Clinical and genomic landscape of RAS mutations in gynecologic cancers

CONCLUSION: RAS mutations in gynecologic cancers have a distinct histopathologic distribution and may impact overall survival. PIK3CA, PTEN, and ARID1A are potentially actionable co-alterations. RAS pathway-targeted therapy should be considered.PMID:38687597 | DOI:10.1158/1078-0432.CCR-23-2819

Source: Clinical Cancer Research - April 30, 2024 Category: Cancer & Oncology Authors: Ji Son Yingao Zhang Heather Lin Oriol Mirallas Pablo Alvarez Ballesteros Mirella Nardo Natalie Clark R Tyler Hillman Erick Campbell Vijaykumar Holla Amber M Johnson Amadeo B Biter Ying Yuan Lauren P Cobb David M Gershenson Amir A Jazaeri Karen H Lu Pamela Source Type: research